Hi friends. The world is changing so fast. Here are two recent cool ideas.
1) Are Psychedelics Moving into Mainstream: Treating Addiction by Turning on the “ENOUGH” switch.
Will psychedelics hold the key to breaking the chains of addiction?
In the midst of a global cultural shift, psychedelics have emerged as a powerful catalyst in 2023, captivating the interest of individuals, researchers, and policymakers alike. With mounting scientific evidence showcasing their potential for therapeutic benefits, psychedelics are transcending their counterculture roots and venturing into the mainstream. This shift has paved the way for pharmaceutical-based psychedelics to revolutionize addiction treatment, offering a mesmerizing twist to the traditional approach. AN INNOVATION FROM ISRAEL.
Leading the charge is Clearmind, a pioneering biotech company at the forefront of psychedelic exploration. Focused on the discovery and development of novel psychedelic-derived therapeutics, Clearmind aims to transform these mind-altering compounds into regulated medicines, foods, or supplements. Their groundbreaking CMND-100, a treatment based on 5-methoxy-2-aminoindane ("MEAI"), signals to the brain a sense of satisfaction and desire for nothing more. MEAI exerts a euphoric alcohol-like experience and a reduced desire to consume alcoholic beverages with the potential to change the lives of millions who struggle to drink in moderation. Clearmind submitted an Investigational New Drug ("IND") application with the U.S. Food and Drug Administration ("FDA"), requesting approval to initiate its first-in-human Phase I/IIa clinical trial with CMND-100 in patients suffering from alcohol use disorder ("AUD"). Pending regulatory approval, the company plans to initiate the CMND-100 trial in 2023.
“We are trying to solve addiction problems. It can be anything between drug abuse, alcohol abuse, obesity, etc. The first indication we’re pursuing is alcohol use disorder or alcoholism.” @Adi Zuloff-Shani @ClearmindCMND INFORMATION ON CLEARMIND MEDICINE
First up, ending alcoholism. Next up, tackling obesity. Are psychedelics the wild unicorns sprinkling magic dust on the path to recovery? Who knows. Stay tuned.
2) A Superplant (Houseplant) with Air-Cleaning Superpowers to Kill Pollution?
In a twist of pandemic-induced serendipity, Neoplants, a Paris-based startup, came up with an ingenious solution to air quality concerns. A botanical superhero — a houseplant on “steroids.” By playing Mother Nature's own genetic engineer, they spliced the resilient genes of extremophile bacteria into the unsuspecting pothos plant, transforming it into an air-cleaning powerhouse. AN INNOVATION FROM FRANCE.
Though all plants naturally pull excess carbon dioxide from the air using photosynthesis, the Neoplants team believes that it’s possible to accelerate the photosynthesis process with the use of genetic engineering. How? These researchers inserted genes from extremophile bacteria, which survive in the environment by eating toxic chemicals. This genetically engineered modification boosted the pothos plant’s pollutant-metabolizing capacity. Neoplants created a plant that can metabolize four major indoor air pollutants and certain VOCs, also including toluene, benzene, and carcinogen (present in wildfire smoke). Their new supercharged plant is called Neo P1 and is considered a new variety of Pothos. They say “Neo P1 is equivalent to up to 30 regular houseplants in terms of air purification. It also doesn't store pollutants as a normal houseplant would do, but recycles them into useful metabolites.” NEOPLANTS INFORMATON @lionel_mora